Summary
Amgen Inc. (AMGN) filed an 8-K on October 17, 2019, to report on an amendment to a material definitive agreement. Specifically, the company entered into Amendment No. 1 to the Asset Purchase Agreement (APA) on October 17, 2019. The material terms of the original APA, which was entered into on August 26, 2019, are detailed in a previous 8-K filing. This filing primarily serves to disclose the execution of this amendment. While the specific details of the amendment are not provided in this 8-K excerpt, it signifies a modification to the previously established asset purchase agreement with Celgene Corporation. Investors should refer to the original August 26, 2019, 8-K filing and the newly filed Amendment No. 1 (Exhibit 10.1) for a comprehensive understanding of the terms and implications of this agreement.
Key Highlights
- 1Amgen Inc. entered into Amendment No. 1 to an Asset Purchase Agreement (APA) on October 17, 2019.
- 2The amendment relates to a material definitive agreement, indicating a significant contractual change.
- 3The original APA was entered into on August 25, 2019, with Celgene Corporation.
- 4The material terms of the original APA were previously disclosed in an 8-K filing on August 26, 2019.
- 5This 8-K filing (filed October 17, 2019) primarily serves to announce the execution of the amendment.
- 6Exhibit 10.1 contains the full text of Amendment No. 1 to the APA.